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http://dx.doi.org/10.1016/j.ccr.2014.03.033SUMMARYLung squamous cell carcinoma (SCC) is a deadly disease for which current treatments are inadequate. We
demonstrate that biallelic inactivation of Lkb1 and Pten in the mouse lung leads to SCC that recapitulates
the histology, gene expression, and microenvironment found in human disease. Lkb1;Pten null (LP) tumors
expressed the squamous markers KRT5, p63 and SOX2, and transcriptionally resembled the basal subtype
of human SCC. In contrast to mouse adenocarcinomas, the LP tumors contained immune populations en-
riched for tumor-associated neutrophils. SCA1+NGFR+ fractions were enriched for tumor-propagating cells
(TPCs) that could serially transplant the disease in orthotopic assays. TPCs in the LP model and NGFR+ cells
in human SCCs highly expressed Pd-ligand-1 (PD-L1), suggesting amechanism of immune escape for TPCs.INTRODUCTION
Lung squamous cell carcinoma (SCC) is a common type of non-
small-cell lung cancer and the second leading cause of death
related to lung cancer, causing approximately 400,000 deathsSignificance
Although many of the molecular alterations underlying human
lenging to model in the mouse, and there are few in vivo mode
disease. The SCC model described herein is an important tool
genesis, including the identity of TPCs and the involvement o
model also provides a platform to study new therapeutic oppor
interaction with the immune cell microenvironment.
590 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.per year worldwide (Cancer Genome Atlas Research Network,
2012; Siegel et al., 2013). Unlike lung adenocarcinoma (ADC),
for which many relevant oncogenic mutations have been defined
and used to develop strategies for targeted therapies, the
genomic landscape of lung SCC is only now emerging. Therelung SCC were recently described, lung SCC has been chal-
ls for the development of novel cancer therapeutics for this
for investigating the molecular mechanisms of SCC carcino-
f the immune microenvironment in tumor progression. This
tunities for lung SCC through the targeting of a TPC-specific
Cancer Cell
Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsare not yet any approved targeted therapies for lung SCC. Unfor-
tunately, therapeutic targets in lung ADC, such as EGFR and
EML4-ALK, do not appear to play major roles in lung SCC
(Rekhtman et al., 2012). This fact underscores the need to
develop a preclinical model of lung SCC in which to define and
test novel therapeutic approaches.
Currently, the field lacks a mouse model in which the intro-
duction of genetic alterations found in human squamous lung
cancers leads to tumors of purely squamous phenotype.Wepre-
viously reported that simultaneous activation of KrasG12D(Kras)
and inactivation of Lkb1 (also known as serine-threonine kinase
11 [Stk11]) in the lung gave rise to multiple lung cancer histol-
ogies, including SCCs (Ji et al., 2007); however, KRASmutations
are very rarely found in human squamous lung tumors. Recently,
it was reported that kinase-dead Ikka knockin mice developed
spontaneous lung SCCs characterized by Ikka downregulation
and marked pulmonary inflammation (Xiao et al., 2013). Sig-
nificant downregulation of Lkb1 was found in IkkaKA/KA lung
SCCs and adjacent lung tissues compared with wild-type lungs.
Together these results indicate that Lkb1 reduction is likely an
important determinant of lung squamous tumorigenesis.
Despite indications that Lkb1 loss may be central to the gener-
ation of squamous cell cancers, deletion of Lkb1 alone is unable
to drive tumor formation (Ji et al., 2007). PTEN (phosphatase
and tensin homolog) is another commonly mutated, deleted, or
epigenetically silenced tumor suppressor in human lung cancers
(Salmena et al., 2008). Importantly, PTEN is altered in 15% of
human SCCs (Cancer Genome Atlas Research Network, 2012).
PTEN negatively regulates the phosphatidylinositol 3-kinase
(PI3K)/AKT pathway, and PI3K pathway gene alterations are
found in more than half of human lung SCCs (Cancer Genome
Atlas Research Network, 2012). In the mouse model, Pten dele-
tion alone in airway basal cells can initiate lung tumor formation,
but with low tumor incidence, long latency, and mixed ADC and
SCC phenotype (Malkoski et al., 2013).
One key feature of tumor development that autochthonous
genetically engineered mouse models provide is a physiologi-
cally relevant tumor microenvironment. All of the models of lung
SCC to date, including the Ikka knockin mice and a model driven
by chronic tuberculosis infection, showed marked pulmonary
inflammation (Nalbandian et al., 2009; Xiao et al., 2013), suggest-
ing that an inflammatory microenvironment is central to the
development of lungSCCs. This is not surprising given that nearly
all humans with lung SCCs have histories of tobacco use that
drives squamous metaplasia, and the development of SCCs is
associated with inflammatory diseases and chronic immuno-
suppression. Both tumor-associated macrophages (TAMs) and
tumor-associated neutrophils (TANs) comprise significant pro-
portions of the inflammatory infiltrates in a wide variety of mouse
tumormodels andhumancancers (Murdochet al., 2008). Neutro-
phils were shown to predominate in human head and neck squa-
mous carcinomas (Trellakis et al., 2011). Neutrophils found in
mouse tumors are phenotypically characterized as polymorpho-
nuclear CD11b+Ly6G+ cells and may be related to a subtype
of myeloid-derived suppressive cells (MDSCs). MDSCs encom-
pass a heterogeneous population of myeloid cells, which share
the ability to suppress T cells through the production of arginase,
the expression of inducible nitric oxide synthase, and other
mechanisms (Dumitru et al., 2012). In the tumor microenviron-ment, accumulated MDSCs are thought to promote tumor
progression through enhancing matrix degradation, tumor cell
proliferation, metastasis, and angiogenesis (Welch et al., 1989).
MDSCs have also been shown to antagonize effector T cell func-
tion, support the generation of immunosuppressive T cell popu-
lations, and inhibit the lysis of tumor cells by cytotoxic T cells or
natural killer (NK) cells (Dumitru et al., 2012). Some MDSCs
have neutrophilic features, but the precise relationship between
these cells and normal polymorphonuclear leukocytes remains
under active investigation. In this paper, we refer to polymorpho-
nuclear cells infiltrating lung cancers as TANs.
Tumorscanalsoevade immunesurveillancebyexpressingmol-
ecules that maintain immune tolerance in peripheral tissues, such
as Pd-ligand-1 (PD-L1), which interacts with the immune receptor
programmed cell death-1 (PDCD1 or PD-1) (Barber et al., 2006).
The PD-1/PD-L1 interaction inhibits CD8+ cytotoxic T lymphocyte
(CTL) proliferation, survival, and effector function and can induce
apoptosis of tumor-infiltrating T cells (Barber et al., 2006); PD-1/
PD-L1 interactions can also promote the differentiation of CD4+
Tcells intoFOXP3+Tregs (Franciscoetal., 2009),whichare known
to further suppress the immune system and cause peripheral im-
mune tolerance in lung cancer patients (Adeegbe and Nishikawa,
2013). Ectopic PD-L1 expression in tumor cells in a syngeneic
transplant model facilitated the escape of the tumor cells from
CTL control (Iwai et al., 2002). Consistent with these findings in
preclinical systems, infusing lung cancer patients with blocking
anti-PD-1/PD-L1 monoclonal antibodies has shown efficacy in
early stage trials, despite limited activity of prior immunotherapies
for lung malignancies (Brahmer et al., 2012; Topalian et al., 2012).
Tumor-propagating cells (TPCs) have the ability to self-renew
and differentiate into the bulk population of the tumor and are
thought to drive both disease recurrence and metastatic spread
(Visvader and Lindeman, 2012). Stem cell antigen-1 (Sca1 or
Ly6a)was reportedasabronchioalveolar stemcell (BASC)marker
in the distal lung and is also enriched in bronchiolar progenitor
cells (Kim et al., 2005; Lee et al., 2014). SCA1+ cells, located
at the bronchioalveolar duct junction, are hyperproliferative in
response tobothoncogenicKrasanddeletionofPten, suggesting
that they are susceptible to neoplastic transformation (Kim et al.,
2005; Tiozzo et al., 2009). In addition, SCA1 can be used to enrich
for TPCs in the lungADCKrasG12D;p53fl/fl (Kras;p53) model (Curtis
et al., 2010). In themoreproximal lung, nervegrowth factor recep-
tor (TNFR superfamily, member 16, Ngfr) is a stem cell marker
for the pseudostratified tracheal epithelium in both human and
mouse; NGFR expression is specifically observed in the p63+
mouse basal stem cells (Rock et al., 2009). NGFR+ basal cells
appear tobe thecellsof origin inaSOX2-inducedmodel of esoph-
ageal SCC, and NGFR has been suggested as a putative marker
for human esophageal SCC TPCs (Huang et al., 2009; Liu et al.,
2013). Despite these clues as to themolecular phenotype of a po-
tential TPC in SCC, no TPC population able to propagate disease
serially has been identified for lung SCC.
Using conditional knockout alleles of both Lkb1 and Pten, we
found that biallelic inactivation of these two tumor suppressors
in the lung resulted in lung tumors with a purely squamous cell
phenotype. These squamous lung tumors were 100% penetrant
and recapitulated thegenetic,molecular, andmicroenvironmental
aspects of the human disease. With this model, the molecular
and genetic mechanisms involved in the pathogenesis of lungCancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc. 591
Figure 1. Biallelic Inactivation of Both Lkb1 and Pten in the Mouse Lung Leads to SCC
(A) Schematic of biallelic inactivation of both Lkb1 and Pten in the mouse lung by Ad-Cre inhalation, followed by tumor dissociation and sorting.
(B) Phenotypic quantification of lung tumor histologies from the indicated conditional mouse models, including KrasG12D (Kras), KrasG12D;p53fl/fl (Kras;p53),
KrasG12D;Lkb1fl/fl (Kras;Lkb1), and KrasG12D;p53fl/fl;Lkb1fl/fl (Kras;p53;Lkb1), Lkb1fl/fl;Ptenfl/fl (Lkb1, Pten) Lkb1fl/fl;Ptenfl/fl;p53fl/fl (Lkb1;Pten;p53), which all rely
upon Ad-Cre inhalation for tumor initiation (mean ± SEM, n = 5 mice per genotype).
(C) Representative H&E-stained sections derived from tumors arising in the Lkb1;Pten mouse model. Yellow arrows indicate specific features on individual
images. (a) Mature squamous cells with aberrant nuclear morphology; (b) large infiltrates of neutrophils in SCC nodules; (c) keratinized cells with markedly dense
eosinophilic cytoplasm surrounded by epithelial cells; (d) well-differentiated SCCwith keratin pearls; (e) SCC nodules in large airways; (f) squamous-like tumor cell
lymphovascular invasion.
Black scale bars represent 200 mm, yellow scale bars represent 50 mm, and the green scale bar represents 25 mm. See also Figure S1.
Cancer Cell
Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCssquamous tumors, including TPCs, microenvironmental factors,
immune tolerance, and potential targets for future therapies, can
be explored.
RESULTS
Lkb1fl/fl;Ptenfl/fl Mice Develop Lung SCCs that
Recapitulate the Human Disease
In order to examine the possibility that Lkb1 and Pten loss would
lead to lung SCC formation, 6- to 8-week-old Lkb1fl/fl, Ptenfl/fl592 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.(Lkb1,Pten or LP) mice were administered Adenovirus-Cre (Ad-
Cre) via intranasal instillation (Figure 1A). In contrast to other
lung-specific geneticmousemodels described to date, including
KrasG12D (Kras), KrasG12D;p53fl/fl (Kras;p53), KrasG12D;Lkb1fl/fl
(Kras;Lkb1), and KrasG12D;p53fl/fl;Lkb1fl/fl (Kras;p53;Lkb1), in
which the predominant phenotypes are ADC or mixed adeno-
squamous cell carcinoma, 100% of the LP mice developed
typical lung SCCs with 40 to 50 week latency (Figure 1B; Figures
S1A and S1B available online). Small malignant nodules with
squamous characteristics were evident at different time points
Cancer Cell
Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsafter Ad-Cre infection, ranging from 30 to 40 weeks. Both Lkb1
and Pten were confirmed to be homozygously deleted by PCR
on genomic DNA from sorted tumor cells (Figure S1C). The LP
tumors were verified as recapitulating human SCC pathology:
within the tumor nodules, mature squamous cells growing in
a solid configuration with aberrant nuclear morphology (Fig-
ure 1Ca), large infiltrates of neutrophils (Figure 1Cb), and kerati-
nized cells or individual cells with markedly dense eosinophilic
cytoplasm were all observed (Figure 1Cc). Tumors showed hall-
marks of well-differentiated SCC, including invading fibrous
stromawith prominent keratinization (keratin pearls) (Figure 1Cd).
In some cases, SCC nodules were visible in airways (Figure 1Ce)
and at later time points showed lymphovascular invasion (Fig-
ure 1Cf). Tumors arose in both the proximal (Figure S1D, yellow
arrow) and distal lung (Figures S1D and S1E, green arrows),
though many nodules appeared to be surrounded completely
by alveolar epithelium. Low-frequency metastatic lesions were
visible in the chest wall of these mice (3 of 78) (Figure S1F).
To confirm the phenotype of the LP tumors, we performed
immunohistochemistry (IHC) for markers used clinically to distin-
guish human lung ADC from lung SCC. TTF1 (also known as
NKX2-1) and SOX2 are genomically amplified in lung ADCs
and SCCs, respectively, and routinely used as histologic
markers (Bass et al., 2009; Weir et al., 2007). In addition, positive
staining for the markers p63 and keratin-5/6 (KRT5/6) appears to
robustly differentiate SCCs from ADCs (Fatima et al., 2012).
Similar to the human SCC samples, the LP tumor nodules dis-
played high expression of p63, KRT5, and SOX2, while TTF1
staining was negative (Figure 2A). The expression patterns of
p63, KRT5, and SOX2 in SCC colocalized with the expression
of epithelial cell adhesion molecule (EpCAM) (Figure 2A). In
contrast, KrasG12D-driven murine ADC and human ADC tissues
were p63, KRT5, and SOX2 negative, while TTF1 staining was
strongly positive, confirming their ADC phenotype (Figure 2A).
Together these data indicate that LP tumors strongly resemble
human SCC by their expression of the classic squamous
markers p63, KRT5/6 and SOX2, and hallmarks of squamous dif-
ferentiation such as keratin deposition.
Next, we compared the transcriptional landscapes of the LP
tumors with those found in primary human tumors. To do this,
the gene expression profiles of 34 human SCC tumors with either
LKB1 or PTEN alterations from the Cancer Genome Atlas (Can-
cer Genome Atlas Research Network, 2012) were compared
with 35 normal human lung tissue samples to generate a list of
genotype-specific SCC genes. In parallel, the gene expres-
sion profiles of LP tumors from three independent mice were
compared with profiles of normal lung from three age-matched
LP mice that never received Ad-Cre. In the human comparison,
8,237 genes were significantly differentially expressed in the
SCCs versus normal human lung, with a corrected p value
(90th percentile false discovery rate) of zero. Compared with
normal, 3,658 genes were upregulated in tumors, and 4,579
were downregulated. In the smaller mouse data set, 2,236 genes
were differentially expressed, with 916 upregulated and 1,320
downregulated (Figure S2A). Comparison of the mouse and hu-
man gene sets yielded 893 genes that were significantly differen-
tially expressed in both human tumors with LKB1 and/or PTEN
alterations and LPmouse SCCs (Figure S2B). Among the shared
upregulated genes were several known squamous-associatedgenes, including SOX2, P63, NOTCH3, HRAS, and several
keratins (KRT5/KRT6). Gene ontogeny analysis demonstrated
enrichment for genes implicated in squamous differentiation
(p = 3.623 1010, Figure 2B). In contrast, the shared downregu-
lated genes were enriched for terminal respiratory unit differenti-
ation, consistent with the idea that SCC more closely resembles
proximal lung cells than distal epithelia (p = 4.07 3 107,
Figure 2C).
Lkb1fl/fl;Ptenfl/fl Lung SCCs Display Unique Gene
Expression, Metabolism, and Downstream Signaling
Pathways
In order to characterize the gene expression profiles specific to
the tumor cells within the mouse LP SCCs, we used fluores-
cence-activated cell sorting (FACS) to enrich for the epithelial
cells (CD45CD31EpCAM+) from LP SCC tumor nodules,
Kras-driven tumor nodules, and normal lung (Figure S3A). We
then contrasted the gene expression profiles of these three
epithelial cell fractions (Figure 3A, p < 0.001). Remarkably, all
of the genes differentially expressed between normal epithelial
and LP tumor cells were likewise differentially expressed when
comparing Kras tumor with LP tumor cells. This result suggests
that Kras tumors retain some gene expression reminiscent of the
normal distal lung epithelial cell, from which they likely arise. In
contrast, LP tumor cells do not resemble ADC or normal distal
lung cells and instead have markers expressed by tracheal basal
cells, as discussed below.
We next focused on the genes that were differentially
expressed in the LP tumor cells when compared with both
Kras tumor cells and normal lung. In this comparison, 408 genes
were upregulated and 297 genes were downregulated, with a log
fold change > 1.8 and an adjusted p value < 0.001 (Table S1).
Selected genes that can be organized by function or family are
illustrated in a heatmap (Figure 3B). Gene sets that were upregu-
lated in LP tumors include the keratin family members, including
Krt5, which we observed by IHC, and other squamous keratins
such as Krt6a, Krt6b, and Krt14. Also highly upregulated in LP
tumors were the transcription factors Sox2 and p63, consistent
with our IHC results, and Slug and Pax9. Among the secreted
proteins and cytokines produced by these tumors were several
Cxcl family members, including Cxcl3, Cxcl7, and Cxcl5, and
members of theWnt,Bmp, and interleukin superfamilies. Several
enzymes that were highly expressed in LP cells included Serpin
family members and arginase1. Lastly, genes for proteins and
receptors known to be localized to the cell membrane that
were highly expressed in LP cells included Sca1, Ngfr, Egfr,
and Pdl1. Ngfr is of particular interest because it is a known
stem cell marker in the tracheal epithelium, and Pdl1 expression
suggests a mechanism of immune evasion for LP tumor cells.
Genes downregulated in LP tumors included Tgfrb3 and
surfactants.
We next used gene set enrichment analysis (GSEA) to query
the pathways and molecular phenotypes specific to the LP tu-
mors (Subramanian et al., 2007). To do this, we queried a rank-
ordered gene list comparing LP EpCAM+ cells to Kras EpCAM+
cells for enrichment of the four known transcriptionally defined
subclasses of human lung SCC (Wilkerson et al., 2010). We
found that the LP model very closely recapitulates the expres-
sion pattern found in the basal subtype of human SCCCancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc. 593
Figure 2. Lung SCCs in Lkb1fl/fl;Ptenfl/fl Mice Closely Recapitulated the Human Disease
(A) Immunohistochemically stained human and mouse ADC and SCC tumors. The SCC canonical markers KRT5, SOX2, and p63 and the ADC canonical marker
TTF1 were used to distinguish the tumor types. EpCAM is an epithelial cell marker, and the expression patterns of p63, KRT5, and SOX2 in SCC colocalized with
EpCAM expression. Scale bars represent 100 mm for all panels.
(B) Microarray expression profiling of normal lung and SCC tumors frommouse and human (see description in text). Upregulated genes in bothmouse and human
SCC were enriched for a squamous differentiation signature.
(C) Downregulated genes from the analysis in (B) were enriched for a normal lung terminal respiratory unit signature.
See also Figure S2.
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Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCs(Figure S3B, p < 0.0001, normalized enrichment score [NES] =
1.9). Gene sets enriched in the LP tumor cells compared with
Kras tumor cells included those positively regulated by AKT1
and mTOR, while a lung-specific KRAS-associated gene set
was enriched in the Kras cells (Figure S3C; p < 0.0001 for
AKT1 and mTOR, p = 0.012 for KRAS). In addition, compared
with tumors driven by Kras, Kras;Lkb1, Kras;Pten, and
Kras;p53;Lkb1, the LP tumors had much stronger p-AKT but594 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.weaker p-ERK staining (Figure 3C; Figure S3D). Together these
data indicate that the oncogenic signaling pathways activated
in the LP tumors predominantly involve AKT andmTOR, whereas
those in Kras tumors involve downstream mediators of RAS
signaling such as MEK and ERK.
To address potential metabolic differences between SCC,
ADC, and normal lung, we profiled the metabolites in each tis-
sue. In addition to the transcriptional differences observed
Figure 3. Lkb1fl/fl;Ptenfl/fl Lung SCCs
Display Unique Gene Expression, Meta-
bolism, and Downstream Signaling Path-
ways
(A) EpCAM+CD31CD45 cells were isolated by
FACS and subject to microarray expression anal-
ysis. Euler diagram illustrating the gene expression
profiles of epithelial cells from LP SCCs, Kras
ADCs, and normal lung tissues.
(B) Heatmap depicting differential expression of
selected genes in LP SCCs, Kras ADCs, and
normal lung tissues as determined by microarray
expression profiling. Red indicates upregulation.
and green indicates downregulation.
(C) Immunohistochemical staining for p-AKT and
p-ERK on LP, Kras, Kras;Lkb1, Kras;Pten, and
Kras;p53;Lkb1 tumor nodules. Scale bars repre-
sent 50 mm for all panels.
(D) Hierarchical clustering by Ward method of
quantitative metabolomic profiling for LP SCC tu-
mors (S), Kras ADC tumors (K), and normal lung
tissues (N).
See also Figure S3 and Tables S1 and S2.
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mors, and normal murine lungs were unique. The metabolic pro-
files of both Kras and LP tumors clustered completely separately
from normal lung. Furthermore, metabolites in Kras tumors and
LP tumors segregated the tumor types into two distinct clusters
(Figure 3D; Table S2). Among the metabolites most significantly
changed in LP cells relative to normal lung were L-arginine
(reduced) and creatine (increased) (Figure S3E), which we
expected because of the increased expression of arginase1 in
these cells, which we confirmed by real-time RT-PCR (Fig-
ure S3F, p < 0.001).
Lkb1fl/fl;Ptenfl/fl Lung SCCs Are Enriched for TANs
As noted histologically, the LP SCC lesions contained large
neutrophilic infiltrates, suggesting that the immune microenvi-
ronment was distinct from the typical TAM-rich microenviron-
ments observed in most mouse Kras- and Kras;p53-driven
ADC models. To better understand the role of the inflammatory
microenvironment in lung SCC versus Kras ADC, immune cellsCancer Cell 25, 590–(CD45+) from LP SCCs and Kras or
Kras;p53 ADCs were compared using
flow cytometry. In Kras and Kras;p53
tumors, TAMs (alveolar macrophages,
CD45+CD11c+CD11bCD103) predo-
minated; however, within the LP tumors,
the CD45+ population contained sig-
nificantly fewer macrophages and more
TANs (CD45+CD11b+Ly6G+) (Figures 4A
and 4B, p < 0.0001). TANs may promote
tumorigenesis by stimulating angiogen-
esis and immunosuppression in the tu-
mor microenvironment (Dumitru et al.,
2013). Interestingly, the prevalence of
TANs increased with tumor burden, as
lung lobes with higher weight (indicative
of higher tumor burden) showed substan-tially more TANs (Figure 4C, p < 0.0001). In contrast, the absolute
counts of T cells, B cells, NK cells, and TAMs decreased with
increasing lobe weight (Figure S4A), suggesting a selective
recruitment and/or proliferation of TANs during SCC tumor
progression.
To further confirm the presence of TANs in LP tumor nodules
in situ, we performed staining for myeloperoxidase (Mpo), a
marker that is highly expressed by TANs in tumor-bearing mice
(Youn et al., 2012). Within the LP SCCs, MPO+ TANs appeared
to be specifically localized to squamous lesions surrounded by
p63+ epithelial cells (Figure 4D; Figure S4B). Conversely, macro-
phages, identified by F4/80+ staining in mouse tissue, were
distributed widely within or around SCC and ADC lesions (Fig-
ure 4D; Figure S4B). Similar patterns were observed in human
samples; MPO staining was strongly positive in 13 of 15 human
primary SCCsamples examined,whereas only 4 of 12 humanpri-
mary ADCs showed staining (Table S3, p = 0.007); macrophages
(CD163+ in human tissue) were scattered in both human ADCs
and SCCs (Figure 4E; Figure S4C). These differences in cell604, May 12, 2014 ª2014 Elsevier Inc. 595
Figure 4. TANs Were the Predominant Inflammatory Cell Population in Lkb1fl/fl;Ptenfl/fl SCC Tumors
(A) Representative flow cytometry plots for Kras ADC and LP SCC dissociated tumors. Plots are gated on live single CD45+ cells. In Kras tumors, tumor TAMs
(CD45+CD11c+CD11bCD103) constituted the majority of CD45+ cells, whereas in LP tumors, TANs (CD45+CD11b+Ly6G+) were predominant. Gating stra-
tegies are also described in Experimental Procedures.
(B) Quantification of inflammatory cell populations in Kras tumors (n = 7), Kras;p53 tumors (n = 8), and Lkb1;Pten tumors (n = 7) by flow cytometry (mean ± SEM,
p < 0.0001).
(C) Quantification of TANs within right lung lobes from samples with progressively increasing weights (shown in Figure S4A), indicating different tumor burdens:
n = 8 for normal lung control (ctrl), n = 5 for mild disease group (tumor plus surrounding tissue weight < 750 mg), n = 5 for severe disease group (tumor plus
surrounding tissue weight > 750 mg) (mean ± SEM; mild versus control p = 0.0034, severe versus control p < 0.0001).
(legend continued on next page)
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Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsinfiltrates between ADC and SCC lesions were clearly evident in
tumors obtained from the mixed histology p53fl/fl;Ptenfl/fl;Lkb1fl/fl
(p53;Lkb1;Pten or PLP) mouse model. In this model, distinct
areas of ADC and SCC were sometimes observed in close prox-
imity in the lung. Confirming their histologic identity, the squa-
mous areas in PLP mice expressed high levels of p63, whereas
the acinar areas were negative. Importantly, staining for MPO
was specific to the SCC area of the tumor, suggesting that
TANs are specifically recruited to SCC lesions (Figure 4F). Simi-
larly, the enrichment for TANs specifically in the areas of SCC tu-
morsbut not in theadjacent ADC tumorswasalsoobserved in the
Kras;Lkb1mousemodel, which also has themixedADCandSCC
histology (Figure S4D).
To further explore the differences between CD45+ fractions
within SCC and ADC lung tumors, we isolated CD45+EpCAM
cells from LP and Kras tumors and performed microarray anal-
ysis. By comparing the gene expression profiles of LP CD45+
cells to LP EpCAM+ cells and Kras CD45+ cells, we constructed
a list of 156 genes significantly enriched in LP CD45+ cells (Ta-
ble S4, adjusted p < 0.025). Among the genes highly expressed
by these cells was Ly6G, further confirming the TAN phenotype
(Youn et al., 2012). By quantitative PCR, we also confirmed that
Mpo, arginase1, and Cxcr2 are enriched in SCC lesions from LP
mice, whereas their expression was negligible in Kras- and
Kras;p53-tumor derived CD45+ cells (p = 0.005, p < 0.001,
and p = 0.0011, respectively; Figure S4E). We then queried
immunologic signatures that were enriched in the ranked or-
dered list of LP versus Kras CD45+ genes. By using two sets
of independently derived signatures comparing monocyte/
macrophages to neutrophils (Abbas et al., 2005; Konuma
et al., 2011), we found a clear enrichment for neutrophil signa-
tures in the LP CD45+ cells, while macrophage signatures were
significantly enriched in the Kras CD45+ cells (Figure 4G) (p <
0.001).
Elevated expression of the chemokine receptor Cxcr2 sug-
gests one mechanism through which the LP EpCAM+ cells are
able to specifically recruit TANs. Many of the CXC-ligand fam-
ily members have neutrophil chemoattractant activity (De Fili-
ppo et al., 2013) and appeared to be upregulated at the tran-
scriptional level in our EpCAM microarray. Therefore, we
assessed the protein concentrations of these cytokines,
including CXCL1, CXCL2, CXCL5, and CXCL7, in bronchoal-
veolar lavage (BAL) fluid from Lkb1;Pten tumor-bearing mice.
Compared with levels observed in BAL fluid isolated from
normal mice, all these chemokines were significantly elevated
in the BAL fluid of LP tumor-bearing mice (Figure S4F, p <
0.002), suggesting a mechanism through which TANs are re-
cruited and stimulated by these tumors. In addition, GCSF,
another essential regulator of neutrophil trafficking (Semerad
et al., 2002), was also elevated in LP BAL fluid (Figure S4F,
p = 0.0002). Together these data confirm that in contrast to(D and E) Representative immunohistochemical staining for MPO, F4/80 (D), and
ADCs.MPO staining indicating neutrophils was positive only in SCC nodules. F4/8
(E). Scale bars represent 200 mm for all panels of (D) and 800 mm for all panels o
(F) Representative immunohistochemical staining on Lkb1;Pten;p53 tumors in w
staining was restricted to the SCC area. Scale bars represent 200 mm for all pan
(G) GSEA was used to confirm the major immune cell types within Lkb1;Pten SC
See also Figure S4 and Tables S3 and S4.murine Kras and Kras;p53 ADC models that contain predom-
inantly macrophages, lung SCCs show accumulation of
TANs, indicating that distinct oncogenic drivers in non-small-
cell lung cancer sculpt the immune microenvironment in
different ways.
Lkb1fl/fl;Ptenfl/fl Lung SCCs Display Hallmarks of
Immune Suppression
We next evaluated the types of T cells present in LP SCC tumors
by flow cytometry. Compared with T cell populations isolated
from normal lung and peritumoral areas, the T cells within LP
tumors were significantly enriched for Tregs, as determined
by FOXP3 staining (Figure 5A). The ratio of CD8+ T cells to
FOXP3+ Tregs within the tumor and surrounding tissues
decreased with increasing tumor burden, indicating that the
levels of immunosuppression rose with disease progression
(Figure 5B, p < 0.0001). The accumulation of Tregs in LP tumors
was further confirmed by immunohistochemical staining for
FOXP3 in LP nodules (Figure 5C). In addition, T cells in LP tu-
mors highly expressed the negative T cell costimulatory mole-
cule programmed cell death protein 1 (PD-1), and increased per-
centages of PD-1-positive T cells (both CD4+ and CD8+)
correlated with increased tumor burden (Figures 5D and 5E,
p < 0.0001). In contrast to the increased PD-1 expression on
T cells, lymphocyte-activation gene 3 (LAG3) and T cell immuno-
globulin domain and mucin domain 3 (TIM3), two other known
immune-modulating proteins, showed modestly increased
expression (Figure S5A). Cytokines in BAL fluids were further
evaluated, including transforming growth factor b (TGF-b) and
interleukin-6 (IL-6). Compared with levels in normal lung, these
cytokines were significantly increased in BAL fluids from LP tu-
mor-bearing mice (Figure S5B, p < 0.0009). Previous reports
have shown that TGF-b and IL-6 promote tumor growth, regu-
late Treg cell development, and cause immunosuppression (Fla-
vell et al., 2010).
Because we observed high levels of Pdl1 in the LP EpCAM+
cells by microarray, and published work suggests that PD-L1
can induce Tregs (Francisco et al., 2009), we further explored
the expression of this immunomodulating protein. PD-L1
expression was first observed on LP tumor cells by IHC (Fig-
ure 5F). High cell surface expression of PD-L1 on EpCAM+
CD45 cells from LP tumors was confirmed by flow cytometry
(Figure 5Ga, p < 0.0001). We further confirmed the Pdl1 expres-
sion with real-time PCR on EpCAM+CD45 cells from normal
lung and LP tumors and observed 6-fold more Pdl1 mRNA in
the LP tumor cells compared with levels in normal distal lung
epithelium (Figure 5Gb, p = 0.0013). The increased numbers
of Tregs, together with the high levels of PD-1 and PD-L1 on
immune and tumor cells, respectively, indicated that immune
suppression may play an important role during lung SCC
tumorigenesis.CD163 (E) in SCCs and ADCs; the mouse slides were LP SCC and Kras-driven
0marksmacrophages inmice (D), while CD163marksmacrophages in humans
f (E).
hich distinct areas of ADC and SCC were adjacently located. p63 and MPO
els.
Cs and Kras ADCs (Abbas et al., 2005; Konuma et al., 2011).
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Figure 5. Lkb1fl/fl;Ptenfl/fl Lung SCCs
Display Hallmarks of Immune Suppression
(A) Representative flow cytometry plots for FOXP3
andCD8 in total CD3+ T cells within LP SCC tumor,
uninduced normal lung, and lung surrounding LP
SCC tumors.
(B) Ratios of CD8+ T cells to FOXP3+ Tregs as
determined with flow cytometry: n = 8 for control
lung, n = 5 for mild disease group, and n = 5 for
severe disease group (p < 0.0001).
(C) Immunohistochemical staining for FOXP3
confirmed the presence of Tregs in LP SCC nod-
ules. Scale bars represent 50 mm for both panels.
(D and E) Quantification the percentage of PD-1
positive cells within the CD8+ (D) and CD4+ (E)
T cell populations: n = 8 for control lung, n = 5 for
mild disease group, and n = 5 for severe disease
group (p < 0.0001).
(F) Representative immunohistochemical staining
for PD-L1 on LP SCC nodules. Scale bars repre-
sent 100 mm for both panels.
(G) (a) Percentage of PD-L1 positive cells within
the EpCAM+CD45-CD31 fraction from LP SCC
as measured by flow cytometry: n = 7 for LP tu-
mors and n = 5 for normal lung (p < 0.0001). (b)
Real-time RT-PCR for Pdl1 mRNA levels in the
indicated EpCAM+ purified cells from SCC tumors
and normal lung tissue: n = 6 for normal lung and
n = 5 for LP SCC tumors (p = 0.0013).
Data are presented as mean ± SEM in (B), (D), (E),
and (G). See also Figure S5.
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Lung SCC TPCs
We next wished to determine if LP SCCs contained distinct TPC
populations. We decided to begin with analysis for two known
stem cell makers, SCA1 and NGFR, which mark BASCs and
tracheal basal cells, respectively. We first examined NGFR
expression on BASCs and SCA1 expression on basal cells. We
found that although nearly 100% of NGFR+ basal cells ex-
pressed SCA1, only 25% of SCA1+ BASCs expressed NGFR
(Figure S6A). Within the EpCAM+CD45 cell populations, LP
tumor cells showed high expression of SCA1 and NGFR, and
LP tumors harbored a unique population of SCA1+NGFR+ cells
that constituted an average of 17.5% of the LP EpCAM+ cells.
Interestingly this population was nearly absent in both Kras
and Kras;p53 ADC models (Figures 6A and 6B, p < 0.0001; Fig-598 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.ures S6B and S6C). Ngfr transcript was
30-fold more abundant in LP tumor cells
than in normal lung or Kras epithelial frac-
tions (Figure S6D, p < 0.0001). NGFR also
specifically stained the LP SCC tumor
lesions but was not detectable in Kras tu-
mor lesions by IHC (Figure 6Ca). Like-
wise, in human primary lung SCCs,
NGFR staining was observed in 11 of 13
samples examined, whereas only 2 of
12 human primary ADC sections had
detectable NGFR staining (Figure 6Cb;
Table S3; p = 0.001). In PLP tumors in
which the ADC and SCC lesions werejuxtaposed, NGFR staining was specific to the SCC side of the
tissue section (Figure 6Cc).
WenextusedFACSto fractionateLPEpCAM+CD31CD45 tu-
mor cells according to SCA1 and NGFR expression for functional
comparisonofTPCcapacity. First, a surrogate in vitro assay for tu-
mor propagation was used. Four distinct populations, SCA1+
NGFR+, SCA1NGFR+, SCA1+NGFR, and SCA1NGFR cells,
were collected and cocultured in Matrigel (BD Biosciences) with
CD45+CD31+ ‘‘support’’ cells isolated from the primary tumors.
The tumor colony-forming ability of Kras and Kras;p53 sorted tu-
mor fractions was also evaluated in the 3D Matrigel system (Fig-
ure S6E). In agreement with previous in vivo results (Curtis et al.,
2010) and validating this assay for TPC capacity, SCA1+ cells
from Kras;p53 tumors were enriched for tumor colony formation
ability (p = 0.0026), but the same was not true for Kras tumors.
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Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsSCA1+NGFR+ cells from LP tumors formed the most tumor col-
onies in 3D cultures, suggesting that they are the fraction enriched
for tumor propagation (Figure 6D, p = 0.0011). The morphology
and histology of the LP tumor colonies were distinct from those
found inKrasorKras;p53 tumor cultures (FigureS6F). By immuno-
fluorescence, the Lkb1;Pten tumor colonies expressed the squa-
mousmarkerp63but not theADC-associatedsurfactantproteinC
(SPC), while both the Kras- and Kras;p53-derived colonies ex-
pressed SPC (Figure S6F).
To determine if SCA1+NGFR+ cells from LP tumors were en-
riched for TPC characteristics in vivo, three major fractions of
the EpCAM+ cells fromprimary LP tumors, SCA1+NGFR+, SCA1+
NGFR, andSCA1NGFR,were transplantedorthotopically into
immunocompromised mouse recipients immediately following
FACS purification (Figure S6G). The fraction of SCA1NGFR+
was not tested, because of its reproducibly small abundance.
Of the four mice that received SCA1+NGFR+ cells, all developed
typical SCC with p63+, SOX2+, and KRT5+ staining within 30 to
40 weeks (Figures 6E and 6F). To assess the presence of self-
renewing TPCs within these tumors, the secondary tumors were
dissected, dissociated, and sorted for NGFR and SCA1, and the
three major fractions were transplanted for tertiary tumor forma-
tion. All mice transplanted with SCA1+NGFR+ developed tertiary
SCC within 11 to 27 weeks (Figure 6E, p = 0.001 for secondary,
p = 0.002 for tertiary, Fisher’s exact test). All primary, secondary,
and tertiary tumors shared the same histological and FACS char-
acteristics (FigureS6H). Together thesedata demonstrate that LP
tumors contained a distinct population of SCA1+NGFR+ TPCs
that could transplant disease retaining squamous characteristics.
TPCs Express High Levels of PD-L1
Little is known about how TPCs escape immunologic clearance
and clonally expand to form malignant tumor nodules. To
address this question, we further quantified the PD-L1 level on
LP tumor cell fractions. By gating the four SCA1;NGFR fractions
and analyzing the percentage of PD-L1+ cells in each fraction,
we found a clear enrichment for PD-L1+ cells within the SCA1+
NGFR+ fraction (Figure 7A). Within a group of seven mice,
an average of 69% of SCA1+NGFR+ cells expressed PD-L1 on
their cell surface, whereas only 39% of SCA1+NGFR or 32%
of SCA1NGFR+ cells were PD-L1+ (Figure 7B, p = 0.004). Like-
wise, by real-time RT-PCR for Pdl1 within the sorted LP tumor
fractions, SCA1+NGFR+ cells had 7-fold more Pdl1 mRNA than
SCA1NGFR cells and about 2-fold more than SCA1+NGFR
or SCA1NGFR+ cells (Figure 7C, p = 0.035). We also used
flow cytometry and real-time RT-PCR to assess PD-L1 levels
in BASCs and basal cells. NGFR+ BASCs expressed the most
PD-L1 in the distal lung, while PD-L1 expression was uniformly
high by flow cytometry in the trachea (Figures S7A and S7B).
In order to explore the relationship between NGFR and PD-L1
expression in patient tissue, we used human lung SCC tissues
that were passaged in immunocompromised mice as patient-
derived xenografts (PDXs) (Figure S7C). Hematoxylin and eosin
(H&E)-stained sections from the PDX samples showed that the
squamous histology of the tumors was retained in the xenograft
model (Figure 7D). PDX samples were dissociated and stained
with antibodies directed against human CD31, CD45, EpCAM,
NGFR, and PD-L1 (Figure S7D). We analyzed the amount of
PD-L1 staining on both EpCAM+NGFR+ and EpCAM+NGFRfractions. Using six different PDX samples, PD-L1 staining was
4.2-fold higher in the NGFR+ fraction relative to the NGFR frac-
tion of the human EpCAM+ tumor cells (Figure 7E, p = 0.02). We
further confirmed this trend with independent human lung SCC
tumor samples by staining serial sections for NGFR and PD-
L1. Clearly, PD-L1 is colocalized to the NGFR+ cells within these
tumors, indicating that the majority of NGFR+ cells coexpress
PD-L1 (Figure 7F). Therefore, in lung SCC, PD-L1 is most abun-
dantly expressed on tumor cells that express NGFR, and if these
cells are analogous to the NGFR+ cells in mouse tumors, they will
also be enriched for TPC activity.
DISCUSSION
Here, we demonstrate that biallelic inactivation of both Lkb1 and
Pten in the mouse lung leads to fully penetrant SCC. Compared
with lung Kras-driven ADC models, the immune microenviron-
ment of these SCCs was enriched for TANs. Furthermore, we
demonstrate that SCA1+NGFR+ tumor cells are enriched for tu-
mor-propagating ability and express high levels of the immune
evasion molecule PD-L1. These tumors very closely recapitulate
the gene expression profiles of the basal subtype of human lung
SCC, indicating that these mice can serve as a valuable model
for understanding progression and maintenance of basal lung
SCCs. This SCCmodel will enable the investigation of themolec-
ular mechanisms of human SCC carcinogenesis and will allow
further preclinical and coclinical investigation of novel therapies
aimed at eradicating lung tumors.
Although lung ADC and SCC occur at relatively equal fre-
quencies worldwide, developing a genetic model of lung SCC
has been challenging. The Ad-Cre inhalation method may spe-
cifically target more distal lung progenitors, thus selecting for
tumor cells of origin that predispose toward an ADC phenotype.
Several studies have targeted deletion of squamous tumor sup-
pressors, such as Pten, or activation of squamous oncogenes,
such as Sox2, but despite these efforts, only partial SCC differ-
entiation was observed in either model (Lu et al., 2010; Malkoski
et al., 2013). Here, we demonstrate that deletion of both Pten
and Lkb1, via the traditional Ad-Cre inhalation system, is able
to produce lung tumors of purely squamous phenotype.
Lkb1;Pten tumor lesions appeared to grow into the distal lung,
suggesting that if basal cells are the cells of origin, they are
able to migrate more distally to propagate disease. When we
examined the expression of stem cell markers in normal lung tis-
sue, 100% of basal cells were SCA1+, while 25% of BASCs
were NGFR+. These data suggest an alternative possibility
that a rare subset of NGFR+ BASCs could serve as distal cells
of origin for these tumors. Surfactant protein C Cre-recombi-
nase and club cell secretory protein Cre-recombinase both
failed to produce tumors when used with the Lkb1;Pten alleles
(data not shown), indicating that distal lung cells may not be
the primary targets of oncogenic transformation in this model.
Further examination of the cells of origin for these tumors,
including the use of basal cell-specific Cre strains or repetitive
injury that targets particular cell populations, will help us under-
stand which lung cells can serve as precursors for these squa-
mous tumors.
As expected, the loss of both Lkb1 and Pten in these tumors
activated the AKT and mTOR pathways, likely driving cellularCancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc. 599
Figure 6. Lkb1fl/fl;Ptenfl/fl Lung SCC Contained SCA1+NGFR+ TPCs that Could Serially Transplant Squamous Disease
(A) Representative flow cytometry plots for NGFR and SCA1 expression within the indicated EpCAM+CD45CD31 dissociated tumor cell populations. LP tumor
cells showed much higher expression of both SCA1 and NGFR than either the Kras or Kras;p53 tumors.
(B) Quantification of SCA1- and NGFR-expressing cells with the EpCAM+CD45CD31 population as assessed by flow cytometry. The percentage of
SCA1+NGFR+ in LP tumors is much higher than in Kras or Kras;p53 tumors: n = 23 for Kras tumors, n = 25 for Kras;p53 tumors, and n = 34 for Lkb1;Pten tumors
(p < 0.0001).
(C) Representative immunohistochemical staining for NGFR on mouse SCC and ADC (a) and human SCC nodules (b). NGFR staining is strongly positive on SCC
tumors but negative on ADC tumors. In the Lkb1;Pten;p53 tumors, distinct areas of ADC and SCC were adjacently located. NGFR staining was restricted to the
SCC area (c). Scale bars represent 50 mm for (a) and (b) and 200 mm for panel (c).
(D) Quantification of tumorspheres derived from SCA1+NGFR+, SCA1NGFR+, SCA1+NGFR, and SCA1NGFR FACS purified cells that were cocultured in
Matrigel with equal amounts of CD45+CD31+ cells from the same primary tumors. Each fraction was seeded at 5,000 tumor cells/well. The colony-propagating
ability of the SCA1+NGFR+ fraction in LP tumors is higher than that of the other fractions (p = 0.0011).
(E) Quantification of tumor propagation ability of FACS-isolated SCA1+NGFR+, SCA1+NGFR, and SCA1NGFR LP tumor cells. The secondary tumors were
derived from intratracheal transplantation, with tumor formation latency of 30 to 40 weeks. The tertiary tumors were derived from intrathoracic injection,
with tumor formation latency of 20 to 30 weeks. Ten thousand sorted cells from each fraction were injected for each fraction and each experiment.
(legend continued on next page)
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Figure 7. SCA1+NGFR+ TPCs in
Lkb1fl/fl;Ptenfl/fl Lung SCCTumor Expressed
High Levels of PD-L1
(A) Representative histogram of PD-L1 expressing
cells from a dissociated LP tumor gated on
DAPIEpCAM+CD45CD31 cells and then for
the four indicated fractions of SCA1;NGFR-ex-
pressing cells. The unstained control trace in gray
is shown for gating. DAPI, 40,6-diamidino-2-phe-
nylindole.
(B) Quantification of PD-L1 expression level
by flow cytometric analysis. PD-L1 expression is
higher in SCA1+NGFR+ population than any other
population (n = 7 tumors, p = 0.004).
(C) Real-time RT-PCR quantification of Pdl1
mRNA expression in SCA1+NGFR+, SCA1
NGFR+, SCA1+NGFR, and SCA1NGFR sorted
populations (n = 7 tumors, p = 0.035).
(D) Representative H&E staining confirming that
PDX tumors retained squamous histology. The
black scale bar represents 200 mm, and the yellow
scale bar represents 2,000 mm.
(E) Quantification of PD-L1 expression level by
flow cytometric analysis of PDX samples. Mean
fluorescence intensities for PD-L1 antibody on
EpCAM+NGFR+ fractions are higher than those
for EpCAM+NGFR fractions. The control is
unstained dissociated PDX cells (n = 6 tumors,
p = 0.02).
(F) Serial sections of formalin-fixed human SCC
tumors stained with H&E, PD-L1, or NGFR. PD-L1
is colocalized to the NGFR+ cells within these tu-
mors. Scale bars represent 100 mm for all panels.
Data are presented as mean ± SEM in (B), (C), and
(E). See also Figure S7.
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also associated with the upregulation of specific cytokines and
other immune-modulating proteins, leading to a unique tumor
microenvironment. Compared with Kras tumor cells, the LP
EpCAM+ cells expressed very high levels of the chemokines
CXCL3 and CXCL5, and the BAL fluid contained elevated
CXCL1, CXCL2, CXCL5, and CXCL7. The CXC chemokine family
controls the migration and adhesion of monocytes and neutro-Only SCA1+NGFR+ populations could form tumors and be serially transplanted (p = 0.001 for secondar
exact test).
(F) Representative immunohistochemical staining on tertiary tumors derived from SCA1+NGFR+ LP tumor cell
squamous histology and were positive for all of the squamous markers examined. Scale bars represent 100
Data are presented as mean ± SEM in (B) and (D). See also Figure S6.
Cancer Cell 25, 590–phils, mediating its effects on target cells
by interacting with CXCR2 (Po˜ld et al.,
2004). CXCL5 is also known as epithe-
lial-derived neutrophil-activating peptide
78, and its expression is associated with
PI3K/AKT and Raf/MEK/ERK activation
(Hsu et al., 2013). Recent findings in tu-
mor-bearing mice and cancer patients
indicate that the increased metabolism
of L-arginine by TANs producing argi-
nase1 can inhibit T cell lymphocyte re-sponses (Raber et al., 2012), and it is likely that this mechanism
is in play in the LP tumors. Furthermore, we observed strong
MPO staining in patient SCC tissues, suggesting that activated
TANs are a key component of SCC in both mouse and human.
In addition to expression of the TAN-attracting cytokines, the
LP EpCAM+ cells expressed high levels of the immune evasion
molecule PD-L1. Recently, there has beenmuch excitement sur-
rounding the potential of targeting molecules such as PD-L1 toy tumors, p = 0.002 for tertiary tumors, Fisher’s
s after intrathoracic injection. The tumors retained a
mm for all panels.
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Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCs‘‘reawaken’’ the immune system and cause tumor destruction. In
the phase 1 study of nivolumab, a fully humanized monoclonal
antibody to PD-1, PD-L1 expression was determined by IHC in
pretreatment tumor biopsies of various tumor types (n = 42).
Thirty-six percent of patients whose tumors showed PD-L1
expression achieved objective response to nivolumab treatment
(9 of 25), while none of the 17 patients with PD-L1-negative tu-
mors showed any objective response, although some achieved
prolonged stable disease (Topalian et al., 2012). These data indi-
cate that PD-L1 expression might influence response to anti-
PD-1 antibody therapy. With the accumulation of clinical data,
the actual correlation between PD-L1 expression and response
to anti-PD-1 therapy should become clearer.
Intriguingly, the TPCs within our SCC model showed enrich-
ment for PD-L1 expression, suggesting that TPCs have unique
immune evasion properties. Strikingly, we found that the
SCA1+NGFR1+ cell population had enhanced tumor-propa-
gating activity compared with other tumor cell populations.
Notably, our studies compared three tumor cell populations
from murine SCC, but the SCA1NGFR+ population could not
be assessed because of low abundance. Thus, there could be
additional TPCs to characterize in Lkb1;Pten SCCs. Further-
more, although PDX analyses showed that NGFR+ human SCC
cells are enriched for PD-L1, we have not yet established the
identity of TPCs in human SCC with a functional assay. SCA1
as a TPCmarker is not useful for human cell studies, andmarkers
in addition to NGFR may be required to enrich for propagating
activity from primary patient SCCs. It is also currently unclear
how universal the immune evasion ability of TPCs we found
will be in human SCC or in other tissues. It will be crucial in future
studies to investigate TPCs in other tumor types and charac-
terize their PD-L1 expression to further explore this intriguing
link between immune escape and tumor propagation. In the
future, it may be possible to first debulk the tumor with a more
generally targeted inhibitor or surgery and then prevent tumor
recurrence and/or metastasis through administration of anti-
PD-1 therapy to target TPCs. Together these data demonstrate
the potential of immunotherapy for the treatment of lung SCC
and lay the groundwork for further investigation into the
response of both cancer cells and the immune microenviron-
ment to such treatments.
EXPERIMENTAL PROCEDURES
Mouse Cohorts and Human Samples
All mice were housed in a biosafety level 2 lab at Dana-Farber Cancer Institute.
All care and treatment of experimental animals were in accordance with Har-
vard Medical School/Dana-Farber Cancer Institute institutional animal care
and use committee guidelines. Detailed mouse cohort information can be
found in Supplemental Experimental Procedures. Patient slides were provided
by the Pathology Department of Brigham and Women’s Hospital. The human
samples were obtained from consented subjects at the Dana-Farber Cancer
Institute/Harvard Cancer Center under institutional review board-approved
protocol 02-180. Frozen PDX tissues were purchased from the Van Andel
Institute.
Flow Cytometry Analysis and Sorting
Tumors were dissected from the lungs of primary mice, and tumor tissue was
prepared as previously described (Curtis et al., 2010). Single-cell suspensions
were stained using rat-antimouse antibodies. Detailed antibody information
and gating strategy can be found in Supplemental Experimental Procedures.602 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.3D Culture and Tumor Transplants
FACS-sortedmouse cells were resuspended inMTEC/Plus containing 20 ng/ml
EGFandFGF2,mixed1:1with growth factor-reducedMatrigel, andpipetted into
a 12-well 0.4 mm Transwell insert (Falcon). MTEC/Plus medium (700 ml) was
added to the lower chamber and refreshed every other day. Intratracheal trans-
plantation was performed as previously described (Curtis et al., 2010). Intratho-
racic injections were performed as previously described (Jongsma et al., 2008).
Metabolomics Profiles Analysis
Metabolite extraction and targeted mass spectrometry analysis for metabo-
lomics profiles were conducted as reported previously (Yuan et al., 2012).
Briefly, the frozen tumors were smashed in cold 80% high-performance liquid
chromatography-grade methanol on dry ice twice, and then the extractions
were Speed Vac/lyophilized to a pellet using no heat. The data were normal-
ized and analyzed with MetaboAnalyst 2.0 (Xia et al., 2012). In hierarchical
cluster analysis, each sample begins as a separate cluster, and the algorithm
proceeds to combine them until all samples belong to one cluster. Clustering
results are shown as heatmap (distancemeasure using Pearson and clustering
algorithm using Ward).
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism (GraphPad Soft-
ware). All numerical data are presented as mean ± SEM. Grouped analysis
was performed using two-way ANOVA. Column analysis was using one-way
ANOVA or Student’s t test. A p value < 0.05 was considered statistically
significant.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the microarray data
reported in this paper is GSE54353.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.03.033.
AUTHOR CONTRIBUTIONS
C.X. and C.M.F. worked closely on the paper. C.X. and C.M.F. contributed to
the experimental design and performed the majority of the experiments. C.X.
was responsible primarily for the mouse model establishment and character-
ization, microenvironment, and immune marker identification. C.M.F. worked
primarily on validating the TPC markers in vitro and in vivo, the bioinformatic
analysis, and tumor microenvironment characterization. C.X. and C.M.F.
contributed to manuscript writing.
ACKNOWLEDGMENTS
We thank the Boston Children’s Hospital flow cytometry facility and members
of the C.F.K. and Zon Labs for helpful discussions. This work was supported in
part by theUnitedAgainst LungCancer and theSusanSpooner Research Fund
(to K.-K.W.); American Cancer Society Post-Doctoral Fellowship PF-12-151-
01-DMC (to C.M.F.); a Margaret A. Cunningham Immune Mechanisms in Can-
cer Research Fellowship Award (to S.K.); American Cancer Society Research
Scholar grant RSG-08-082-01-MGO, the V Foundation for Cancer Research,
a Basil O’Conner March of Dimes Starter Award, the Harvard Stem Cell Insti-
tute, and the LungCancerResearchFoundation (toC.F.K.); theCancerPreven-
tionResearch Institute of Texas (RP100550); and grantsHL090136, HL100402,
CA122794, CA140594, CA163896, CA166480, P0CA154303, CA098101,
CA141576, CA137181, P0CA120964, CA143083, andCA163677 from theNIH.
Received: November 18, 2013
Revised: January 29, 2014
Accepted: March 31, 2014
Published: May 1, 2014
Cancer Cell
Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsREFERENCES
Abbas, A.R., Baldwin, D., Ma, Y., Ouyang, W., Gurney, A., Martin, F., Fong, S.,
van Lookeren Campagne, M., Godowski, P., Williams, P.M., et al. (2005).
Immune response in silico (IRIS): immune-specific genes identified from a
compendium of microarray expression data. Genes Immun. 6, 319–331.
Adeegbe, D.O., and Nishikawa, H. (2013). Natural and induced T regulatory
cells in cancer. Front Immunol. 4, 190.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H.,
Freeman, G.J., and Ahmed, R. (2006). Restoring function in exhausted CD8
T cells during chronic viral infection. Nature 439, 682–687.
Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim,
S.Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified
lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
Nat. Genet. 41, 1238–1242.
Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P.,
Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. (2012). Safety and ac-
tivity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.
366, 2455–2465.
Cancer Genome Atlas Research Network. (2012). Comprehensive genomic
characterization of squamous cell lung cancers. Nature 489, 519–525.
Curtis, S.J., Sinkevicius, K.W., Li, D., Lau, A.N., Roach, R.R., Zamponi, R.,
Woolfenden, A.E., Kirsch, D.G., Wong, K.K., and Kim, C.F. (2010). Primary tu-
mor genotype is an important determinant in identification of lung cancer prop-
agating cells. Cell Stem Cell 7, 127–133.
De Filippo, K., Dudeck, A., Hasenberg, M., Nye, E., van Rooijen, N., Hartmann,
K., Gunzer,M., Roers, A., and Hogg, N. (2013). Mast cell andmacrophage che-
mokines CXCL1/CXCL2 control the early stage of neutrophil recruitment dur-
ing tissue inflammation. Blood 121, 4930–4937.
Dumitru, C.A., Moses, K., Trellakis, S., Lang, S., and Brandau, S. (2012).
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophe-
notyping, cell biology and clinical relevance in human oncology. Cancer
Immunol. Immunother. 61, 1155–1167.
Dumitru, C.A., Lang, S., and Brandau, S. (2013). Modulation of neutrophil gran-
ulocytes in the tumor microenvironment: mechanisms and consequences for
tumor progression. Semin. Cancer Biol. 23, 141–148.
Fatima, N., Cohen, C., Lawson, D., and Siddiqui, M.T. (2012). Combined dou-
ble CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell
carcinoma. Diagn. Cytopathol. 40, 943–948.
Flavell, R.A., Sanjabi, S., Wrzesinski, S.H., and Licona-Limo´n, P. (2010). The
polarization of immune cells in the tumour environment by TGFbeta. Nat.
Rev. Immunol. 10, 554–567.
Francisco, L.M., Salinas, V.H., Brown, K.E., Vanguri, V.K., Freeman, G.J.,
Kuchroo, V.K., and Sharpe, A.H. (2009). PD-L1 regulates the development,
maintenance, and function of induced regulatory T cells. J. Exp. Med. 206,
3015–3029.
Hsu, Y.L., Hou, M.F., Kuo, P.L., Huang, Y.F., and Tsai, E.M. (2013). Breast
tumor-associated osteoblast-derived CXCL5 increases cancer progression
by ERK/MSK1/Elk-1/Snail signaling pathway. Oncogene. 32, 4436–4447.
Huang, S.D., Yuan, Y., Liu, X.H., Gong, D.J., Bai, C.G., Wang, F., Luo, J.H., and
Xu, Z.Y. (2009). Self-renewal and chemotherapy resistance of p75NTRpositive
cells in esophageal squamous cell carcinomas. BMC Cancer 9, 9.
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., and Minato, N. (2002).
Involvement of PD-L1 on tumor cells in the escape from host immune system
and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U S A 99,
12293–12297.
Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P.,
Torrice, C., Wu, M.C., Shimamura, T., Perera, S.A., et al. (2007). LKB1 modu-
lates lung cancer differentiation and metastasis. Nature 448, 807–810.
Jongsma, J., vanMontfort, E., Vooijs, M., Zevenhoven, J., Krimpenfort, P., van
der Valk, M., van de Vijver, M., and Berns, A. (2008). A conditional mouse
model for malignant mesothelioma. Cancer Cell 13, 261–271.Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S.,
Crowley, D., Bronson, R.T., and Jacks, T. (2005). Identification of bronchioal-
veolar stem cells in normal lung and lung cancer. Cell 121, 823–835.
Konuma, T., Nakamura, S., Miyagi, S., Negishi, M., Chiba, T., Oguro, H., Yuan,
J., Mochizuki-Kashio, M., Ichikawa, H., Miyoshi, H., et al. (2011). Forced
expression of the histone demethylase Fbxl10 maintains self-renewing
hematopoietic stem cells. Exp. Hematol. 39, 697–709.e5.
Lee, J.H., Bhang, D.H., Beede, A., Huang, T.L., Stripp, B.R., Bloch, K.D.,
Wagers, A.J., Tseng, Y.H., Ryeom, S., and Kim, C.F. (2014). Lung stem cell
differentiation in mice directed by endothelial cells via a BMP4-NFATc1-
thrombospondin-1 axis. Cell 156, 440–455.
Liu, K., Jiang, M., Lu, Y., Chen, H., Sun, J., Wu, S., Ku, W.Y., Nakagawa, H.,
Kita, Y., Natsugoe, S., et al. (2013). Sox2 cooperates with inflammation-medi-
ated Stat3 activation in the malignant transformation of foregut basal progen-
itor cells. Cell Stem Cell 12, 304–315.
Lu, Y., Futtner, C., Rock, J.R., Xu, X., Whitworth, W., Hogan, B.L., and Onaitis,
M.W. (2010). Evidence that SOX2 overexpression is oncogenic in the lung.
PLoS ONE 5, e11022.
Malkoski, S.P., Cleaver, T.G., Thompson, J.J., Sutton, W.P., Haeger, S.M.,
Rodriguez, K.J., Lu, S.L., Merrick, D., and Wang, X.J. (2013). Role of PTEN
in basal cell derived lung carcinogenesis. Mol. Carcinog. Published online
April 26, 2013. http://dx.doi.org/10.1002/mc.22030.
Murdoch, C., Muthana, M., Coffelt, S.B., and Lewis, C.E. (2008). The role of
myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8,
618–631.
Nalbandian, A., Yan, B.S., Pichugin, A., Bronson, R.T., and Kramnik, I. (2009).
Lung carcinogenesis induced by chronic tuberculosis infection: the experi-
mental model and genetic control. Oncogene 28, 1928–1938.
Po˜ld, M., Zhu, L.X., Sharma, S., Burdick, M.D., Lin, Y., Lee, P.P., Po˜ld, A., Luo,
J., Krysan, K., Dohadwala, M., et al. (2004). Cyclooxygenase-2-dependent
expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5
and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res.
64, 1853–1860.
Raber, P., Ochoa, A.C., and Rodrı´guez, P.C. (2012). Metabolism of L-arginine
by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppres-
sion and therapeutic perspectives. Immunol. Invest. 41, 614–634.
Rekhtman, N., Paik, P.K., Arcila, M.E., Tafe, L.J., Oxnard, G.R., Moreira, A.L.,
Travis, W.D., Zakowski, M.F., Kris, M.G., and Ladanyi, M. (2012). Clarifying the
spectrum of driver oncogenemutations in biomarker-verified squamous carci-
noma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Clin. Cancer Res. 18, 1167–1176.
Rock, J.R., Onaitis, M.W., Rawlins, E.L., Lu, Y., Clark, C.P., Xue, Y., Randell,
S.H., and Hogan, B.L. (2009). Basal cells as stem cells of the mouse trachea
and human airway epithelium. Proc. Natl. Acad. Sci. U S A 106, 12771–12775.
Salmena, L., Carracedo, A., and Pandolfi, P.P. (2008). Tenets of PTEN tumor
suppression. Cell 133, 403–414.
Semerad, C.L., Liu, F., Gregory, A.D., Stumpf, K., and Link, D.C. (2002). G-CSF
is an essential regulator of neutrophil trafficking from the bone marrow to the
blood. Immunity 17, 413–423.
Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics, 2013. CA
Cancer J. Clin. 63, 11–30.
Subramanian, A., Kuehn, H., Gould, J., Tamayo, P., and Mesirov, J.P.
(2007). GSEA-P: a desktop application for gene set enrichment analysis.
Bioinformatics 23, 3251–3253.
Tiozzo, C., De Langhe, S., Yu, M., Londhe, V.A., Carraro, G., Li, M., Li, C., Xing,
Y., Anderson, S., Borok, Z., et al. (2009). Deletion of Pten expands lung epithe-
lial progenitor pools and confers resistance to airway injury. Am. J. Respir. Crit.
Care Med. 180, 701–712.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C.,
McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B.,
et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N. Engl. J. Med. 366, 2443–2454.
Trellakis, S., Bruderek, K., Dumitru, C.A., Gholaman, H., Gu, X., Bankfalvi, A.,
Scherag, A., Hu¨tte, J., Dominas, N., Lehnerdt, G.F., et al. (2011).Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc. 603
Cancer Cell
Lkb1;Pten-Null Lung SCCs Harbor PD-L1+ TPCsPolymorphonuclear granulocytes in human head and neck cancer: enhanced
inflammatory activity, modulation by cancer cells and expansion in advanced
disease. Int. J. Cancer 129, 2183–2193.
Visvader, J.E., and Lindeman, G.J. (2012). Cancer stem cells: current status
and evolving complexities. Cell Stem Cell 10, 717–728.
Weir, B.A., Woo, M.S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W.M.,
Province, M.A., Kraja, A., Johnson, L.A., et al. (2007). Characterizing the
cancer genome in lung adenocarcinoma. Nature 450, 893–898.
Welch, D.R., Schissel, D.J., Howrey, R.P., and Aeed, P.A. (1989). Tumor-
elicited polymorphonuclear cells, in contrast to ‘‘normal’’ circulating poly-
morphonuclear cells, stimulate invasive and metastatic potentials of rat
mammary adenocarcinoma cells. Proc. Natl. Acad. Sci. U S A 86, 5859–
5863.
Wilkerson, M.D., Yin, X., Hoadley, K.A., Liu, Y., Hayward, M.C., Cabanski,
C.R., Muldrew, K., Miller, C.R., Randell, S.H., Socinski, M.A., et al. (2010).604 Cancer Cell 25, 590–604, May 12, 2014 ª2014 Elsevier Inc.Lung squamous cell carcinoma mRNA expression subtypes are reproducible,
clinically important, and correspond to normal cell types. Clin. Cancer Res. 16,
4864–4875.
Xia, J., Mandal, R., Sinelnikov, I.V., Broadhurst, D., and Wishart, D.S. (2012).
MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis.
Nucleic Acids Res. 40 (Web Server issue), W127–W133.
Xiao, Z., Jiang,Q.,Willette-Brown, J., Xi, S., Zhu, F., Burkett, S., Back, T., Song,
N.Y., Datla,M., Sun, Z., et al. (2013). The pivotal role of IKKa in the development
of spontaneous lung squamous cell carcinomas. Cancer Cell 23, 527–540.
Youn, J.I., Collazo,M., Shalova, I.N., Biswas, S.K., andGabrilovich, D.I. (2012).
Characterization of the nature of granulocytic myeloid-derived suppressor
cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167–181.
Yuan, M., Breitkopf, S.B., Yang, X., and Asara, J.M. (2012). A positive/negative
ion-switching, targeted mass spectrometry-based metabolomics platform for
bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872–881.
